Inhibition of PPARγ by Natural Compounds as a Promising Strategy in Obesity and Diabetes

Alessandra Ammazzalorso*, Rosa Amoroso
Department of Pharmacy, University G. d’Annunzio, Via dei Vestini 31, 66100 Chieti, Italy

Article Metrics

CrossRef Citations:
Total Statistics:

Full-Text HTML Views: 935
Abstract HTML Views: 335
PDF Downloads: 143
ePub Downloads: 118
Total Views/Downloads: 1531
Unique Statistics:

Full-Text HTML Views: 778
Abstract HTML Views: 257
PDF Downloads: 95
ePub Downloads: 77
Total Views/Downloads: 1207

© 2019 Ammazzalorso and Amoroso.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: ( This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Correspondence: Address correspondence to this author at the Department of Pharmacy, University “G. d’Annunzio”, Via dei Vestini 31, 66100 Chieti, Italy; Tel: +39-0871-3554682; Fax: +39-0871-3554911;E-mail:


A wide group of natural compounds (flavonoids, stilbenes, neolignans and others) has been identified as Peroxisome Proliferator-Activated Receptor (PPAR) agonists, with a large variety of chemical structure and different activity versus the three PPAR subtypes. These receptors are transcription factors controlling metabolic pathways in the organism, involved in lipid and glucose metabolism, cell differentiation and energy homeostasis. Otherwise, very little is known about natural compounds able to inhibit PPARs. A number of studies demonstrate that PPARγ repression has a beneficial effect in reducing body weight and improving insulin sensitivity, suggesting a potential clinical role in obesity and type 2 diabetes. This review analyzes natural compounds able to repress PPAR activity and their potential use in metabolic disorders.

Keywords: PPAR antagonist, Natural compound, Antidiabetic, Adipocyte differentiation, Antiobesity, Metabolic disorders.